Nerviano Medical Sciences S.r.l. names Alberto Ocana, PhD, as Global Clinical Lead
Nerviano Italy, 11 September 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Alberto Ocana PhD, has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. In this pivotal role, […]
Nerviano Medical Sciences Announces Enhanced US Executive Team: Terrence West, MBA, Expands Role as Chief Operating Officer
NERVIANO, IT and BOSTON, Mass., August 1, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. […]
Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia
Nerviano 22 June 2023_Nerviano Medical Sciences Srl (NMS), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to announce the FDA Clearance of Investigational New Drug (IND) Application for NMS-03592088 (NMS-088), a novel, potent FLT3 inhibitor. NMS-088 is poised to transform the landscape of […]
Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates
NERVIANO, Italy, June 5, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS Group S.p.A. (NMS group), the largest cancer research and development company in Italy, announced signing of a license agreement and right of option with Solve Therapeutics, Inc. (SolveTx) to develop and commercialize novel antibody-drug conjugates (ADCs) for […]
Nerviano Medical Sciences S.r.l. to Present MPSA-153-001 at ASCO 2023: Slide deck, Poster and Video Preview
Nerviano Medical Sciences S.r.l. to Present MPSA-153-001 at ASCO 2023: Slide deck, Poster and Video Preview NMS-153: A clinical-phase, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 with differentiated mechanism of action and potential for First in Class/Best in Class Nerviano, 26 May 2023 – Nerviano Medical Sciences Srl, a member […]
Nerviano Medical Sciences Appointed Paramjit Kaur, PhD to Accelerate PERK/GCN2 Inhibitor Asset Development
NERVIANO, May 17th 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Paramjit Kaur, PhD has joined the Global Asset Leadership Team to lead the strategy and the […]
Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting NMS-153: A clinical-phase, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 with differentiated mechanism of action and potential for First in Class/Best in Class Nerviano, 15 May 2023 – Nerviano Medical Sciences Srl, a […]
1st European Cancer Dependency Map Symposium successfully concluded in Milan on May 9th, sponsored by Nerviano Medical Sciences S.r.l.
Nerviano 9 May 2023_ Nerviano Medical Sciences Srl (NMS) was delighted to be the title sponsor of the 1st European Cancer Dependency Map Symposium, together with Astra Zeneca. This is an international event organized by scientists at Human Technopole, EMBL – European Bioinformatics Institute (Cambridge, UK), Wellcome Sanger Institute (Cambridge, UK) and ETH Zurich (Switzerland) […]
Nerviano Medical Sciences included as AACR 2023 Plenary Session highlights for its NMS-03592088 Phase 1 Clinical Trial Data in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia
Nerviano 21 April 2023_Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to be included as Plenary Session highlights of the AACR (American Association for Cancer Research) Annual Meeting 2023 for the data from the First-In-Human study of […]
Nerviano Medical Sciences Announces Phase 1 Clinical Trial Data for NMS-03592088 in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia
Nerviano 16 April 2023_Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the First-In-Human study of NMS-03592088, a novel, potent inhibitor of FLT3, KIT and CSF1R were presented during an oral scientific session at the […]
